Advancing TNFR2-Directed Treg Modulation Through Mechanistic Validation & Clinical Development

4:30 pm - Wednesday 24th March 2027

  • Presenting proof-of-mechanism findings, including data from a Phase Ia healthy volunteer study, to inform TNFR2-targeted development strategies
  • Highlighting emerging mechanistic insights into Treg and TNFR2 biology to support differentiation within the Treg therapeutic landscape
  • Exploring opportunities to expand the impact of Treg-modulating therapies in dermatological, gastrointestinal, and other autoimmune and inflammatory diseases

Speakers:

Chief Scientific Officer
TRex Bio Inc.